Neuroblastoma Overview
Neuroblastoma is a rare type of cancer that mostly affects babies and young children. It develops from specialized nerve cells (neuroblasts) left behind from a baby’s development in the womb. Neuroblastoma most commonly occurs in 1 of the adrenal glands situated above the kidneys, or in the nerve tissue that runs alongside the spinal cord in the neck, chest, tummy or pelvis. It can spread to other organs, such as the bone marrow, bone, lymph nodes, liver and skin.
“Neuroblastoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroblastoma Market.
The Neuroblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Neuroblastoma Pipeline Report:
Route of Administration
Neuroblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Molecule Type
Products have been categorized under various Molecule types, such as
Neuroblastoma Pipeline Therapeutics Assessment
DelveInsight’s Neuroblastoma Report covers around 35+ products under different phases of clinical development like-
Some of the key companies in the Neuroblastoma Therapeutics Market include:
Key companies developing therapies for Neuroblastoma are – Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, K C Pharmaceuticals Inc., Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, Autolus, NanoPharmaceuticals, Aptorum Group, and others.
Emerging Neuroblastoma Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Neuroblastoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/neuroblastoma-pipeline-insight
Neuroblastoma Pipeline Analysis:
The Neuroblastoma pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Neuroblastoma product details are provided in the report. Download the Neuroblastoma pipeline report to learn more about the emerging Neuroblastoma therapies
Neuroblastoma Pipeline Market Drivers
Neuroblastoma Pipeline Market Barriers
Scope of Neuroblastoma Pipeline Drug Insight
Request for Sample PDF Report for Neuroblastoma Pipeline Assessment and clinical trials
Table of Contents
1
Neuroblastoma Report Introduction
2
Neuroblastoma Executive Summary
3
4
Neuroblastoma- Analytical Perspective In-depth Commercial Assessment
5
Neuroblastoma Pipeline Therapeutics
6
Neuroblastoma Late Stage Products (Phase II/III)
7
Neuroblastoma Mid Stage Products (Phase II)
8
Neuroblastoma Early Stage Products (Phase I)
9
Neuroblastoma Preclinical Stage Products
10
Neuroblastoma Therapeutics Assessment
11
Neuroblastoma Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Neuroblastoma Key Companies
14
Neuroblastoma Key Products
15
Neuroblastoma Unmet Needs
16
Neuroblastoma Market Drivers and Barriers
17
Neuroblastoma Future Perspectives and Conclusion
18
Neuroblastoma Analyst Views
19
Appendix
20
About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Neuroblastoma drugs and therapies
Media ContactCompany Name: DelveInsight Business ResearchContact Person: Gaurav BoraEmail: Send EmailPhone: 8774225362Address:27 Drydock Ave S. Jones Blvd #2432City: BostonState: MACountry: United StatesWebsite: https://www.delveinsight.com/consulting/asset-prioritizaton-services